UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 353

Sortiert nach

EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate

Journal of controlled release, 2024-10, Vol.374, p.171-180

2024

Volltextzugriff (PDF)

Trastuzumab: updated mechanisms of action and resistance in breast cancer

Frontiers in oncology, 2012, Vol.2, p.62-62

2012

Volltextzugriff (PDF)

Activating HER3 mutations in breast cancer

Oncotarget, 2018-06, Vol.9 (45), p.27773-27788

2018

Volltextzugriff (PDF)

Long road towards effective HER3 targeting in breast cancer

Cancer treatment reviews, 2024-09, Vol.129, p.102786, Article 102786

2024

Volltextzugriff (PDF)

Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers

Oncotarget, 2020-01, Vol.11 (1), p.31-45

2020

Volltextzugriff (PDF)

HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway

Genes & diseases, 2024-06, p.101354, Article 101354

2024

Volltextzugriff (PDF)

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

Annals of oncology, 2023-08, Vol.34 (8), p.670-680

2023

Volltextzugriff (PDF)

Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade

Cancer cell, 2018-05, Vol.33 (5), p.922-936.e10

2018

Volltextzugriff (PDF)

Clinical development of HER3-targeting monoclonal antibodies: Perils and progress

Cancer treatment reviews, 2018-07, Vol.68, p.111-123

2018

Volltextzugriff (PDF)

Role of human epidermal growth factor receptor 3 in treatment resistance of anaplastic lymphoma kinase translocated non-small cell lung cancer

Cancer biology & therapy, 2023-12, Vol.24 (1), p.2256906-2256906

2023

Volltextzugriff (PDF)

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2019-08, Vol.24 (8), p.1095-1102

2019

Volltextzugriff (PDF)

Understanding the biology of HER3 receptor as a therapeutic target in human cancer

Acta pharmaceutica Sinica. B, 2018-07, Vol.8 (4), p.503-510

2018

Volltextzugriff (PDF)

NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells

International journal of oncology, 2017-11, Vol.51 (5), p.1553-1562

2017

Volltextzugriff (PDF)

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors

Investigational new drugs, 2021-12, Vol.39 (6), p.1604-1612

2021

Volltextzugriff (PDF)

AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib

Biochemical pharmacology, 2022-10, Vol.204, p.115228-115228, Article 115228

2022

Volltextzugriff (PDF)

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

European journal of pharmacology, 2024-08, Vol.977, p.176725, Article 176725

2024

Volltextzugriff (PDF)

Corosolic acid inhibits colorectal cancer cells growth as a novel HER2/HER3 heterodimerization inhibitor

British journal of pharmacology, 2021-03, Vol.178 (6), p.1475-1491

2021

Volltextzugriff (PDF)

Comparative evaluation of [sup.111]In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors

Oncology reports, 2015-08, p.1042

2015

Volltextzugriff (PDF)

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

Future oncology (London, England), 2024-02, Vol.20 (16), p.1057-1067

2024

Volltextzugriff (PDF)

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer

Oncotarget, 2017-10, Vol.8 (51), p.89284-89306

2017

Volltextzugriff (PDF)

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Cancer and metastasis reviews, 2017-03, Vol.36 (1), p.141-157

2017

Volltextzugriff (PDF)

HER3 in cancer: from the bench to the bedside

Journal of experimental & clinical cancer research, 2022-10, Vol.41 (1), p.1-310, Article 310

2022

Volltextzugriff (PDF)

Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3

Peptides (New York, N.Y. : 1980), 2022-10, Vol.156, p.170858-170858, Article 170858

2022

Volltextzugriff (PDF)

Ultrasensitive electrochemical detection of cancer associated biomarker HER3 based on anti-HER3 biosensor

Talanta (Oxford), 2014-03, Vol.120, p.355-361

2014

Volltextzugriff (PDF)

1 – 25 von 353

Suche als RSS-Feed

Aktive Filter

ThemaEgfr

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(303)
Mit Volltextzugriff
(330)

Publikationsform

Sprache

Englisch
(353)
Japanisch
(72)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate

Trastuzumab: updated mechanisms of action and resistance in breast cancer

Activating HER3 mutations in breast cancer

Long road towards effective HER3 targeting in breast cancer

Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers

HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade

Clinical development of HER3-targeting monoclonal antibodies: Perils and progress

Role of human epidermal growth factor receptor 3 in treatment resistance of anaplastic lymphoma kinase translocated non-small cell lung cancer

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer

Understanding the biology of HER3 receptor as a therapeutic target in human cancer

NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors

AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

Corosolic acid inhibits colorectal cancer cells growth as a novel HER2/HER3 heterodimerization inhibitor

Comparative evaluation of [sup.111]In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

HER3 in cancer: from the bench to the bedside

Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3

Ultrasensitive electrochemical detection of cancer associated biomarker HER3 based on anti-HER3 biosensor

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

Aktive Filter

Suchergebnisse filtern